[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100395681":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":26,"responsibleParty":41,"collaborators":26,"id":44,"slug":26,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":26,"eligibilityCriteria":48,"healthyVolunteers":45,"sex":49,"minAge":50,"maxAge":26,"enrollmentInfo":51,"targetDuration":26,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":26,"overallStatus":62,"whyStopped":26,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":26},{"fullName":5,"class":6},"Henry Ford Health System","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm B: Oral Dexamethasone","EXPERIMENTAL","Participants will be randomly assigned to receive 4 mg Oral Dexamethasone taken twice daily for 4 days",[13],"Drug: Dexamethasone",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm A: Placebo","PLACEBO_COMPARATOR","Participants will be randomly assigned to receive 4 mg placebo taken twice daily for 4 days",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Dexamethasone","4 mg bid for 4 days",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","oral placebo",[15],[32],{"name":33,"affiliation":5,"role":34},"Jason Davis, M.D.","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Jonathan Shaw, M.D.","CONTACT","414-405-8544","jshaw5@hfhs.org",{"type":34,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Jonathan H. Shaw","Orthopaedic Surgeon","100395681",false,"NCT04432259","Oral Dexamethasone as an Intervention for Postoperative Pain and Nausea Management in Total Knee Arthroplasty","Inclusion Criteria:\n\n* adult patients age 18 and older who will be undergoing joint replacement\n\nExclusion Criteria:\n\n* Patients with uncontrolled diabetes ( HbA1C, \\>7.5%), impaired hepatic function (Child class, \\>B), impaired renal failure (Glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2), chronic narcotic use, alcohol and\u002For opioid dependence, patients with a known adverse reaction to corticosteroids, and patients unable to give informed consent.","ALL","18 Years",{"count":52,"type":53},300,"ESTIMATED","INTERVENTIONAL",[56],"PHASE4","This study aims to determine if oral dexamethasone provides clinically significant improvement in postoperative outcomes, specifically nausea and pain scores.",[59,60,61],"Arthritis Knee","Postoperative Nausea","Postoperative Pain","NOT_YET_RECRUITING","2020-06-12",{"date":65,"type":66},"2020-06-16","ACTUAL",{"date":68,"type":53},"2020-07",{"date":70,"type":53},"2022-12",{"name":5,"class":6}]